________________________________________________________
____Explicit____
135..140
0,1,1,1,1,1,1,2,3,2,0
#### Text ####
while
##############
#### Features ####
Ot, Ftv, Null, Null
38..65
0,1,1,0;0,1,1,1,0;0,1,1,1,1,0;0,1,1,1,1,1,0
#### Text ####
they discovered an antibody
##############
while, Comparison.Contrast.Opposition, Temporal.Synchrony
____Arg1____
66..134
0,1,1,1,1,1,1,0;0,1,1,1,1,1,1,1;0,1,1,1,1,1,1,2,0;0,1,1,1,1,1,1,2,1;0,1,1,1,1,1,1,2,2;0,1,1,1,1,1,1,2,3,0;0,1,1,1,1,1,1,2,3,1
#### Text ####
that, in laboratory test-tube experiments, kills AIDS-infected cells
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
141..165
0,1,1,1,1,1,1,2,3,2,1
#### Text ####
preserving healthy cells
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
169..171
1,0,0
#### Text ####
If
##############
#### Features ####
Wr, Comm, Null, Null
if, Contingency.Condition.Hypothetical
____Arg1____
208..299
1,1;1,2;1,3;1,4
#### Text ####
the work would represent a major advance in research on acquired immune deficiency syndrome
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
172..206
1,0,1
#### Text ####
further experiments are successful
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
301
2
#### Features ####
Wr, Comm, Null, Null
because, Contingency.Cause.Reason
____Arg1____
169..299
1
#### Text ####
If further experiments are successful, the work would represent a major advance in research on acquired immune deficiency syndrome
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
301..418
2
#### Text ####
The drug AZT, the only treatment currently on the market, claims only to help stop the spread of AIDS, not to cure it
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
422..425
3,0
#### Text ####
But
##############
#### Features ####
Wr, Comm, Null, Null
but, Comparison.Concession.Contra-expectation
____Arg1____
9..165
0
#### Text ####
Two Japanese scientists said they discovered an antibody that, in laboratory test-tube experiments, kills AIDS-infected cells while preserving healthy cells
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
426..606
3,1;3,2;3,3
#### Text ####
several analysts and Japanese scientists familiar with the study, which was announced at a conference in Nagoya yesterday, expressed skepticism over the significance of the results
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
608..611
4,0
#### Text ####
And
##############
#### Features ####
Wr, Comm, Null, Null
and, Expansion.Conjunction
____Arg1____
422..490;549..606
3,0;3,1,0;3,1,1,0;3,1,1,1,0;3,1,1,1,1,0;3,1,1,1,1,1;3,1,1,1,1,3;3,2;3,3
#### Text ####
But several analysts and Japanese scientists familiar with the study expressed skepticism over the significance of the results
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
612..754
4,1;4,2;4,3
#### Text ####
the researchers themselves acknowledged they still must do much more work before they can say whether the treatment would actually cure humans
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
657..662
4,2,1,1,1
#### Text ####
still
##############
#### Features ####
Wr, Comm, Null, Null
still, Comparison.Concession.Contra-expectation
____Arg1____
169..299
1
#### Text ####
If further experiments are successful, the work would represent a major advance in research on acquired immune deficiency syndrome
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
652..656;663..754
4,2,1,0;4,2,1,1,0;4,2,1,1,2
#### Text ####
they must do much more work before they can say whether the treatment would actually cure humans
##############
#### Features ####
Ot, Ftv, Null, Null
612..651
4,1;4,2,0;4,3
#### Text ####
the researchers themselves acknowledged
##############
________________________________________________________
________________________________________________________
____Explicit____
686..692
4,2,1,1,2,1,2,0
#### Text ####
before
##############
#### Features ####
Ot, Ftv, Null, Null
612..651
4,1;4,2,0;4,3
#### Text ####
the researchers themselves acknowledged
##############
before, Temporal.Asynchronous.Precedence
____Arg1____
652..685
4,2,1,0;4,2,1,1,0;4,2,1,1,1;4,2,1,1,2,0;4,2,1,1,2,1,0;4,2,1,1,2,1,1
#### Text ####
they still must do much more work
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
693..754
4,2,1,1,2,1,2,1
#### Text ####
they can say whether the treatment would actually cure humans
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
994..998
6,1
#### Text ####
then
##############
#### Features ####
Ot, Comm, Null, Null
758..854
5,0;5,1,0;5,2
#### Text ####
Shin Yonehara, a research scientist at the Tokyo Metropolitan Institute of Medical Science, said
##############
then, Temporal.Asynchronous.Precedence
____Sup1____
936..979
5,1,1,1,1,1,1,1,1,3
#### Text ####
which is characteristic of an infected cell
##############
____Arg1____
888..934
5,1,1,1,1,1,0;5,1,1,1,1,1,1,0;5,1,1,1,1,1,1,1,0;5,1,1,1,1,1,1,1,1,0;5,1,1,1,1,1,1,1,1,1;5,1,1,1,1,1,1,1,1,2
#### Text ####
by recognizing an antigen called a Fas-antigen
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
981..993;999..1013
6,0;6,2;6,3
#### Text ####
The antibody kills the cell
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1209
8
#### Features ####
Wr, Comm, Null, Null
in fact, Expansion.Restatement.Specification
____Arg1____
1121..1207
7,1,1,1,1,1
#### Text ####
that the antibody wiped out an average of 60% of AIDS-infected cells within three days
##############
#### Features ####
Ot, Comm, Null, Null
1096..1120
7,1,1,0;7,1,1,1,0;7,1,1,1,1,0
#### Text ####
their experiments showed
##############
____Arg2____
1209..1276
8,0
#### Text ####
In some of the experiments, it killed almost all the infected cells
##############
#### Features ####
Ot, Comm, Null, Null
1278..1298
8,1;8,2;8,3;8,4
#### Text ####
the researchers said
##############
________________________________________________________
________________________________________________________
____Explicit____
1300..1309
9,0
#### Text ####
Meanwhile
##############
#### Features ####
Wr, Comm, Null, Null
meanwhile, Comparison.Contrast.Juxtaposition, Temporal.Synchrony
____Arg1____
1096..1276
7,1,1;8,0
#### Text ####
their experiments showed that the antibody wiped out an average of 60% of AIDS-infected cells within three days.
In some of the experiments, it killed almost all the infected cells
##############
#### Features ####
Ot, Comm, Null, Null
1017..1095
7,0;7,1,0;7,2
#### Text ####
Dr. Yonehara and his partner, Nobuyuki Kobayashi of Yamaguchi University, said
##############
____Arg2____
1311..1358
9,1;9,2;9,3;9,4
#### Text ####
fewer than 10% of the healthy cells were killed
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
1385..1390
10,1,1,1,1,1,0,0
#### Text ####
still
##############
#### Features ####
Ot, Comm, Null, Null
1362..1374
10,0;10,1,0;10,2
#### Text ####
The two said
##############
still, Comparison.Concession.Contra-expectation
____Arg1____
1096..1276;1300..1358
7,1,1;8,0;9
#### Text ####
their experiments showed that the antibody wiped out an average of 60% of AIDS-infected cells within three days.
In some of the experiments, it killed almost all the infected cells Meanwhile, fewer than 10% of the healthy cells were killed
##############
#### Features ####
Ot, Comm, Null, Null
1017..1095
7,0;7,1,0;7,2
#### Text ####
Dr. Yonehara and his partner, Nobuyuki Kobayashi of Yamaguchi University, said
##############
____Arg2____
1375..1384;1391..1443
10,1,1,0;10,1,1,1,0;10,1,1,1,1,0;10,1,1,1,1,1,0,1;10,1,1,1,1,1,0,2;10,1,1,1,1,1,1;10,1,1,1,1,1,2;10,1,1,1,1,1,3
#### Text ####
they must do more laboratory tests, then experiment on animals
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
1417..1421
10,1,1,1,1,1,2
#### Text ####
then
##############
#### Features ####
Ot, Comm, Null, Null
1362..1374
10,0;10,1,0;10,2
#### Text ####
The two said
##############
then, Temporal.Asynchronous.Precedence
____Arg1____
1375..1415
10,1,1,0;10,1,1,1,0;10,1,1,1,1,0;10,1,1,1,1,1,0;10,1,1,1,1,1,1
#### Text ####
they must still do more laboratory tests
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1422..1443
10,1,1,1,1,1,3
#### Text ####
experiment on animals
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1445
11
#### Features ####
Wr, Comm, Null, Null
also, Expansion.Conjunction
____Arg1____
1362..1443
10
#### Text ####
The two said they must still do more laboratory tests, then experiment on animals
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1445..1530
11
#### Text ####
They said they hoped to conduct tests on human patients in the U.S. by late next year
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
1532
12
#### Features ####
Wr, Comm, Null, Null
because, Contingency.Cause.Reason
____Arg1____
1455..1530
11,1,1
#### Text ####
they hoped to conduct tests on human patients in the U.S. by late next year
##############
#### Features ####
Ot, Comm, Null, Null
1445..1454
11,0;11,1,0;11,2
#### Text ####
They said
##############
____Arg2____
1532..1621
12,0
#### Text ####
Japan doesn't have enough AIDS patients to do significant experimentation in that country
##############
#### Features ####
Ot, Comm, Null, Null
1623..1632
12,1;12,2;12,3;12,4
#### Text ####
they said
##############
________________________________________________________
________________________________________________________
____Explicit____
1747..1750
14,0
#### Text ####
But
##############
#### Features ####
Wr, Comm, Null, Null
but, Comparison.Contrast.Juxtaposition
____Arg1____
1636..1745
13
#### Text ####
The announcement got wide exposure in the Japanese media, and even moved some pharmaceutical stocks yesterday
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
1907..1969
14,2,3
#### Text ####
I'm not so optimistic of its future use in therapeutic methods
##############
#### Features ####
Ot, Comm, Null, Null
1751..1904
14,1;14,2,0;14,2,1;14,2,2;14,3;14,4
#### Text ####
Takashi Kitamura, director of the biology department at Japan's National Institute of Health and secretary of the government's AIDS-research center, said
##############
________________________________________________________
________________________________________________________
____Implicit____
1980
15
#### Features ####
Ot, Comm, Null, Null
1972..1979
15,0;15,1,0;15,2
#### Text ####
He said
##############
because, Contingency.Cause.Reason
____Arg1____
1907..1969
14,2,3
#### Text ####
I'm not so optimistic of its future use in therapeutic methods
##############
#### Features ####
Ot, Comm, Null, Null
1747..1904
14,0;14,1;14,2,0;14,2,1;14,2,2;14,3;14,4
#### Text ####
But Takashi Kitamura, director of the biology department at Japan's National Institute of Health and secretary of the government's AIDS-research center, said
##############
____Arg2____
1980..2095
15,1,1
#### Text ####
some infected cells may not have the relevant antigen and so wouldn't be killed even after exposure to the antibody
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
2038..2040
15,1,1,1,1,2,0
#### Text ####
so
##############
#### Features ####
Ot, Comm, Null, Null
1972..1979
15,0;15,1,0;15,2
#### Text ####
He said
##############
so, Contingency.Cause.Result
____Arg1____
1980..2033
15,1,1,0;15,1,1,1,0;15,1,1,1,1,0
#### Text ####
some infected cells may not have the relevant antigen
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2034..2037;2041..2095
15,1,1,1,1,1;15,1,1,1,1,2,1;15,1,1,1,1,2,2;15,1,1,1,1,2,3
#### Text ####
and wouldn't be killed even after exposure to the antibody
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
2331..2334
18,0
#### Text ####
But
##############
#### Features ####
Wr, Comm, Null, Null
but, Comparison.Contrast
____Arg1____
2275..2329
17,1,1,1,1,1
#### Text ####
the antibody could potentially kill all infected cells
##############
#### Features ####
Ot, PAtt, Null, Null
2259..2274
17,1,1,0;17,1,1,1,0;17,1,1,1,1,0
#### Text ####
that he thought
##############
____Arg2____
2360..2444
18,2,1
#### Text ####
there were still several uncertainties, particularly regarding possible side effects
##############
#### Features ####
Ot, Comm, Null, Null
2335..2359
18,1;18,2,0;18,3
#### Text ####
he and Dr. Yonehara said
##############
________________________________________________________
________________________________________________________
____Explicit____
2371..2376
18,2,1,1,1,1
#### Text ####
still
##############
#### Features ####
Wr, Comm, Null, Null
still, Comparison.Contrast
____Arg1____
2275..2329
17,1,1,1,1,1
#### Text ####
the antibody could potentially kill all infected cells
##############
#### Features ####
Ot, PAtt, Null, Null
2259..2274
17,1,1,0;17,1,1,1,0;17,1,1,1,1,0
#### Text ####
that he thought
##############
____Arg2____
2360..2370;2377..2444
18,2,1,0;18,2,1,1,0;18,2,1,1,1,0;18,2,1,1,1,2
#### Text ####
there were several uncertainties, particularly regarding possible side effects
##############
#### Features ####
Ot, Comm, Null, Null
2335..2359
18,1;18,2,0;18,3
#### Text ####
he and Dr. Yonehara said
##############
________________________________________________________
________________________________________________________
____Implicit____
2447
19
#### Features ####
Wr, Comm, Null, Null
for example, Expansion.Instantiation
____Arg1____
2360..2444
18,2,1
#### Text ####
there were still several uncertainties, particularly regarding possible side effects
##############
#### Features ####
Ot, Comm, Null, Null
2331..2359
18,0;18,1;18,2,0;18,3
#### Text ####
But he and Dr. Yonehara said
##############
____Arg2____
2447..2547
19,1
#### Text ####
Our antibody specifically killed infected cells at a very low dose, but it can also kill other cells
##############
#### Features ####
Ot, Comm, Null, Null
2550..2567
19,0;19,2;19,3;19,4;19,5;19,6
#### Text ####
said Dr. Yonehara
##############
________________________________________________________
________________________________________________________
____Explicit____
2515..2518
19,1,2
#### Text ####
but
##############
#### Features ####
Ot, Comm, Null, Null
2550..2567
19,0;19,2;19,3;19,4;19,5;19,6
#### Text ####
said Dr. Yonehara
##############
but, Comparison.Contrast
____Arg1____
2447..2513
19,1,0
#### Text ####
Our antibody specifically killed infected cells at a very low dose
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2519..2547
19,1,3
#### Text ####
it can also kill other cells
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
2526..2530
19,1,3,1,1
#### Text ####
also
##############
#### Features ####
Ot, Comm, Null, Null
2550..2567
19,0;19,2;19,3;19,4;19,5;19,6
#### Text ####
said Dr. Yonehara
##############
also, Expansion.Conjunction
____Arg1____
2447..2513
19,1,0
#### Text ####
Our antibody specifically killed infected cells at a very low dose
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2515..2525;2531..2547
19,1,2;19,1,3,0;19,1,3,1,0;19,1,3,1,2
#### Text ####
but it can kill other cells
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
2570
20
#### Features ####
Ot, Comm, Null, Null
2550..2567
19,0;19,2;19,3;19,4;19,5;19,6
#### Text ####
said Dr. Yonehara
##############
in short, Expansion.Restatement.Equivalence
____Arg1____
2447..2547
19,1
#### Text ####
Our antibody specifically killed infected cells at a very low dose, but it can also kill other cells
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2570..2628
20
#### Text ####
We don't know the effect of our antibody on the human body
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
2754..2757
21,4
#### Text ####
but
##############
#### Features ####
Wr, Comm, Null, Null
but, Comparison.Concession.Contra-expectation
____Sup1____
2688..2750
21,2
#### Text ####
the government reports about 1,000 known carriers of the virus
##############
____Arg1____
2633..2684
21,0
#### Text ####
AIDS isn't considered a widespread problem in Japan
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2758..2874
21,5
#### Text ####
many companies have poured substantial resources into research in recent years, hoping to cash in on a possible cure
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
2948..2951
22,1,1,2
#### Text ####
and
##############
#### Features ####
Ot, Comm, Null, Null
2878..2895
22,0;22,1,0;22,2
#### Text ####
Dr. Kitamura said
##############
and, Expansion.Conjunction
____Arg1____
2896..2946
22,1,1,0
#### Text ####
about 35 projects are currently under way in Japan
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
2952..3078
22,1,1,3
#### Text ####
that Japanese researchers in the past year have made available three possible cures to American researchers for clinical tests
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Implicit____
3088
23
#### Features ####
Wr, Comm, Null, Null
furthermore, Expansion.Conjunction
____Arg1____
2896..3078
22,1,1
#### Text ####
about 35 projects are currently under way in Japan, and that Japanese researchers in the past year have made available three possible cures to American researchers for clinical tests
##############
#### Features ####
Ot, Comm, Null, Null
2878..2895
22,0;22,1,0;22,2
#### Text ####
Dr. Kitamura said
##############
____Arg2____
3088..3239
23,1,1
#### Text ####
that when scientists from the two countries meet again in January in New Orleans, the Japanese will present at least three more drugs for human testing
##############
#### Features ####
Ot, Comm, Null, Null
3080..3087
23,0;23,1,0;23,2
#### Text ####
He said
##############
________________________________________________________
________________________________________________________
____Explicit____
3093..3097
23,1,1,1,0,0
#### Text ####
when
##############
#### Features ####
Ot, Comm, Null, Null
3080..3087
23,0;23,1,0;23,2
#### Text ####
He said
##############
when, Temporal.Synchrony
____Arg1____
3088..3092;3170..3239
23,1,1,0;23,1,1,1,1;23,1,1,1,2;23,1,1,1,3
#### Text ####
that the Japanese will present at least three more drugs for human testing
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3098..3168
23,1,1,1,0,1
#### Text ####
scientists from the two countries meet again in January in New Orleans
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
3324
25
____Arg1____
3243..3322
24
#### Text ####
AZT is the world's only prescription medicine approved for treating the disease
##############
____Arg2____
3324..3414
25
#### Text ####
Wellcome PLC, a major British pharmaceutical maker, sells the drug under the name Retrovir
##############
________________________________________________________
________________________________________________________
____Explicit____
3502..3505
27,0
#### Text ####
But
##############
#### Features ####
Wr, Comm, Null, Null
but, Comparison.Contrast
____Arg1____
3418..3500
26
#### Text ####
A Wellcome spokesman declined to comment on the discovery of the antibody in Japan
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3506..3711
27,1;27,2;27,3
#### Text ####
Andrew Porter, a drug-industry analyst at Nikko Securities Co. in London, said if the product were to be successfully developed it would represent "a potential threat to the long-term viability of Retrovir
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____Explicit____
3585..3587
27,2,1,1,0,0
#### Text ####
if
##############
#### Features ####
Ot, Comm, Null, Null
3506..3584
27,1;27,2,0;27,3
#### Text ####
Andrew Porter, a drug-industry analyst at Nikko Securities Co. in London, said
##############
if, Contingency.Condition.Unreal present
____Arg1____
3634..3711
27,2,1,1,1;27,2,1,1,2
#### Text ####
it would represent "a potential threat to the long-term viability of Retrovir
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
3588..3633
27,2,1,1,0,1
#### Text ####
the product were to be successfully developed
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
